CONMED (NYSE:CNMD) Issues Quarterly Earnings Results, Beats Estimates By $0.14 EPS

CONMED (NYSE:CNMD) announced its earnings results on Wednesday. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.14, Zacks reports. CONMED had a net margin of 10.23% and a return on equity of 13.84%. CONMED updated its FY 2025 guidance to 4.250-4.400 EPS.

CONMED Stock Down 0.0 %

Shares of CNMD traded down $0.03 during mid-day trading on Friday, reaching $67.33. 333,643 shares of the stock traded hands, compared to its average volume of 443,924. The company has a quick ratio of 1.06, a current ratio of 2.27 and a debt-to-equity ratio of 1.01. CONMED has a 12-month low of $61.05 and a 12-month high of $88.60. The stock has a fifty day simple moving average of $70.53 and a 200 day simple moving average of $70.20. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of 15.90, a P/E/G ratio of 1.04 and a beta of 1.46.

CONMED Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 3rd. Stockholders of record on Friday, December 20th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date was Friday, December 20th. CONMED’s dividend payout ratio is presently 18.87%.

Wall Street Analysts Forecast Growth

CNMD has been the topic of several research analyst reports. Stifel Nicolaus boosted their price objective on CONMED from $72.00 to $75.00 and gave the company a “buy” rating in a report on Thursday. JPMorgan Chase & Co. lowered shares of CONMED from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $85.00 to $70.00 in a research note on Thursday. StockNews.com downgraded CONMED from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Wells Fargo & Company dropped their price objective on CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a research note on Thursday. Finally, Needham & Company LLC dropped their price objective on shares of CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a research note on Thursday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, CONMED has an average rating of “Moderate Buy” and an average price target of $77.20.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.